Using Pharmacotherapy to Treat Tobacco Dependence in Primary Care Settings

Author: Tammy L. H. Sims, MD, MS, Assistant Professor of Pediatrics, Center for Tobacco Research and Intervention, University of Wisconsin Medical School, Madison, WI.

Peers Reviewer: Michael W. Fel泽, MD, Associate Professor, Department of Family Medicine, Medical College of Georgia, Augusta.

Smoking cessation interventions delivered by primary care physicians are essential in preventing the morbidity and mortality resulting from tobacco use. This article summarizes the major findings of the United States Public Health Service guideline: Treating Tobacco Use and Dependence (USPHS guideline), a comprehensive, evidence-based strategy for treating tobacco dependence. It also provides recommendations for delivering effective clinical interventions to treat tobacco dependence in the primary care setting including behavioral therapies, first-line medications, and second-line medications. The article concludes with updated information about new medications under development. Primary care physicians can implement the strategies recommended by the USPHS guideline to treat their patients by identifying tobacco users, advising them to quit, assessing their willingness to quit, assisting them in quit attempts, and arranging follow-up care for those dependent on tobacco. After reading this article, primary care clinicians will:

1) Understand the rationale for treating tobacco dependence;
2) Recognize why tobacco dependence is a chronic disease;
3) Be familiar with the 5 A’s for providing brief clinical interventions for tobacco users willing to quit;
4) Be familiar with the 5 R’s for motivating tobacco users not yet willing to make a quit attempt; and
5) Know the first-line medications proven to be effective for treating tobacco dependence. Note: This article contains information about an off-label use of nortriptyline and combined nicotine replacement therapies on pages 79 and 82, and information about new drugs in development on pages 83-84.
—The Editor

Definition of Problem

Tobacco use is the leading cause of preventable morbidity and mortality in the United States. Primary care physicians have an extraordinary opportunity to affect the health of their patients who use tobacco by providing evidence-based interventions to encourage smoking cessation. Approximately 84% of all lung cancer deaths in the United States are attributable to smoking and/or environmental tobacco smoke exposure. Furthermore, about 30% of all cancer deaths are caused by smoking. In total, cigarette smoking and exposure to environmental tobacco smoke accounts for more than 400,000 deaths annually in the United States. Tobacco use is a primary cause of many of the diseases that lead patients to fill primary care offices each day, including angina, coronary artery disease, lung cancer, acute bronchitis, chronic obstructive pulmonary disease (COPD), myocardial infarction (MI), stroke, and asthma. By providing brief counseling and pharmacotherapies effective in treating tobacco dependence, clinicians can increase smoking
cessation rates of patients seen in primary care practices. In 1996, the then Agency for Health Care Policy and Research (now the Agency for Health Care Research and Quality) published clinical practice guidelines for smoking cessation, the first comprehensive, evidence-based guideline for the treatment of tobacco addiction in the clinical setting. In 2000, the U.S. Public Health Service published an updated version of the guideline, *Treating Tobacco Use and Dependence*, that is based on the screening and systematic review of 6,000 journal articles. The guideline contains strategies and recommendations to help clinicians, tobacco-dependence treatment specialists, health administrators, and insurers deliver effective, evidence-based interventions to patients dependent on tobacco. This article will focus on USPHS guideline recommendations designed to help primary care clinicians treat their patients who are dependent on tobacco, giving particular attention to the brief clinical interventions and medications that are useful in the primary care setting.

**Epidemiology of Tobacco Use**

In 2001, the prevalence of smoking among adults 18 and older in the United States was 22.8%; 25.2% of men and 20.7% of women were current smokers. While this represents enormous progress since the early 1960s when 44% of all adults smoked, almost 50 million Americans continue to use tobacco regularly.

Age. Most people try their first cigarette and become regular smokers during adolescence. Smoking prevalence among ado-

lescents rose dramatically during the 1990s. Though rates have leveled off, more than 20% of high school students continue to smoke.

**Gender.** Among adult males and females, the prevalence of smoking among men is slightly greater than among women, and men have been consistently heavier smokers than women. Among adolescents in the United States, the prevalence of smoking among males and females is similar. Lung cancer now has surpassed breast cancer as the leading cause of cancer death among women.

**Ethnicity/Race.** In the U.S. adult population, the prevalence of tobacco use is highest among American Indians and Alaska Natives, followed by Caucasians and African-Americans, and lowest among Hispanic Americans and Asian/Pacific Islander Americans. In the U.S. adolescent population, based on data from 12th-grade students, the prevalence of tobacco use is highest among American Indians, followed by whites, then Hispanics. African-American teenagers have the lowest prevalence of tobacco use.

**Socioeconomic Status.** Smoking prevalence is inversely related to level of education, such that those with 16 or more years of education have the lowest smoking rates. Currently, more than 30% of high school dropouts smoke, while only about 12% of college graduates smoke. Also, the prevalence of smoking among blue-collar and service workers is higher than among white-collar workers. Moreover, blue-collar workers are more likely to be heavy smokers. Persons who live below the poverty line are more likely to smoke than those who live at or above the poverty line.

**Basic Neurobiology of Tobacco Dependence**

Nicotine is a potent substance with multiple physiological effects, including powerful psychoactive effects. Nicotinic receptors are distributed throughout the central nervous system. These receptors facilitate the release of different neurotransmitters, including acetylcholine, norepinephrine, dopamine, serotonin, and β-endorphins. Nicotine activates the brain reward system by increasing dopamine release. This brain reward system is the common pathway for pleasurable activities (e.g., sexual activity, eating) and for most drugs of addiction. Arterial nicotine levels increase markedly—within 15 seconds—after inhaling smoke from a cigarette into the lungs. Over time, this rapid delivery of nicotine to the central nervous system leads to tolerance to nicotine, which leads to an increase in cigarette consumption. Between cigarettes, the level of nicotine quickly declines and permits re-sensitization of receptors to the effects of the next cigarette. Individuals tend to smoke more frequently and heavily to obtain the desired effects of nicotine and avoid the unpleasant effects of withdrawal. Nicotine replacement therapy medications are designed to minimize withdrawal symptoms during the quitting process. In contrast to cigarettes and other tobacco products, nicotine replacement therapies have a much slower rate of absorption and delivery of nicotine and do not produce high plasma nicotine levels, which explains their minimal addictive potential. Also, nicotine replacement therapies supply nicotine in a safe manner, without the other
Table 1. Ask — Systematically Identify All Tobacco Users at Every Visit

<table>
<thead>
<tr>
<th>ACTION</th>
<th>STRATEGIES FOR IMPLEMENTATION</th>
</tr>
</thead>
<tbody>
<tr>
<td>Implement an office-wide system that ensures that, for every patient at every clinic visit, tobacco-use status is queried and documented.†</td>
<td>Expand the vital signs to include tobacco use or use an alternative universal identification system.†</td>
</tr>
</tbody>
</table>

VITAL SIGNS

<table>
<thead>
<tr>
<th>Blood Pressure:</th>
<th>Pulse:</th>
<th>Weight:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Temperature:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Respiratory Rate:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tobacco Use: (circle one)</td>
<td>Current</td>
<td>Former</td>
</tr>
</tbody>
</table>

* Repeated assessment is not necessary in the case of the adult who never used tobacco or has not used tobacco for many years, and for whom this information is documented clearly in the medical record.
† Alternatives to expanding the vital signs are to place tobacco-use status stickers on all patient charts or to indicate tobacco-use status using electronic medical records or computer reminder systems.

harmful, carcinogenic components contained in tobacco smoke.

Clinical Management

Primary care providers are in an ideal position to help individuals addicted to tobacco. Seventy percent (70%) of smokers visit a physician each year,19 and most report that advice by a clinician is an important motivator in making a quit attempt.20 In fact, a recent survey of smokers in the United States revealed that 52% tried to quit during the preceding year.21 Despite the availability of assistance in the form of medications and behavioral therapy, an estimated 90% of smoking cessation attempts are unassisted (i.e., cold turkey), resulting in low, long-term success rates (3%-5%).22 The first step in providing assistance in the primary care setting is to identify all tobacco users consistently so that clinicians are made aware of the need for intervention.

To achieve this first step, health care systems should be altered to promote the systematic identification of tobacco users during any and all health care visits.8 Once tobacco users are identified, protocols that utilize the 5 A's (Ask, Advise, Assess, Assist, Arrange) outlined in the USPHS guideline should be used to address this disease properly and provide patients with evidence-based assistance known to improve quitting success rates. Given the chronic nature of tobacco dependence, providers must intervene by advising users to quit, assessing the willingness to quit, assisting users in quitting, and arranging follow-up care. Studies have shown that even brief smoking cessation treatment by health care providers can be effective.21-23 Providers are well positioned to advise smokers to quit, provide appropriate interventions (counseling and medication), provide referrals to quitlines or community programs, and arrange follow up visits to treat this chronic disease.

In addition to counseling, all smokers trying to quit should receive pharmacotherapy except in special circumstances, which include medical contraindications, pregnant/breastfeeding women, adolescent smokers, and those patients who smoke fewer than 10 cigarettes per day. In the presence of any of the above special circumstances, providers must weigh the risks and benefits of medications being considered. Research has shown that the use of nicotine replacement therapy or other pharmacological treatments significantly increase a smoker’s chance of successfully quitting. It is equally important, however, to encourage these smokers to use some form of behavioral counseling (e.g., face-to-face, group, telephone, Internet) along with their pharmacological therapy. Effective strategies for smoking cessation include combined behavioral interventions and pharmacotherapy. With a combination of these interventions, a twofold or more increase in the rate of smoking cessation can be achieved.24 Tobacco addiction is a chronic disease requiring repeated interventions by clinicians who should see each encounter as an opportunity to reach smokers. Most tobacco users attempt cessation five or more times, typically cycling through multiple periods of relapse and remission, before experiencing long-term success.25 This information should be used to guide treatment of tobacco dependence, which will involve ongoing chronic care, rather than one-time acute care. Treatment for tobacco dependence should be much like the type of care provided for other chronic diseases (e.g., diabetes and hypertension) and include repetitive, health education-type counseling and advice, as well as necessary adjustments in medication type and/or dose. Relapse should not be viewed as therapeutic failure, nor failure on the part of the patient, but as evidence of the addictiveness of tobacco and the chronic nature of tobacco dependence.

The 5 A’s Model

To reach large numbers of smokers, systems must be in place for the identification and documentation of all smokers. The USPHS guideline recommends the 5 A’s model—Ask, Advise, Assess, Assist, Arrange—for intervening in the primary care setting with patients to identify and treat those using tobacco. These intervention strategies are designed to be brief, requiring three to five minutes to administer.

Ask About Tobacco Use. Ask every patient, at every visit about smoking status and document the information in the medical record. The USPHS guideline recommends that smoking status be included as a vital sign, with chart stickers or with a computerized reminder system. (See Table 1.)

Advise to Quit. Once identified, all tobacco users should receive clear, strong, direct, personalized advice to quit using tobacco products. The advice should be clear that quitting—not just cutting down—is best. It should be strong and direct in reference to the burden of diseases caused by or exacerbated by smoking. It should be personalized to the health condition and life circumstances of the individual patient. (See Table 2.)
patient recommit to abstinence, help them to problem solve, and assess medication effectiveness and or side effects. (See Table 6.)

**Nonpharmacologic Behavioral Therapy (Individual, Group, or Proactive Telephone Counseling)**

Ideal treatment for tobacco dependence includes behavioral therapy in addition to pharmacotherapy. Behavioral therapy in conjunction with medications has yielded quit rates of 30-40% at one-year follow-up, compared with medication-alone quit rates that reach 15-25%. Behavioral interventions can be delivered in a variety of settings, which have been proven effective in smoking cessation interventions, including individual counseling, group counseling and proactive telephone counseling. These counseling interventions should provide patients with three essential elements to increase their chances of successful abstinence: 1) problem-solving skills training; 2) social support as part of treatment; and 3) help locating and securing social support outside of treatment. Clinicians can help their patients think about and identify situations that increase their risk of relapsing back to smoking, and develop stress management and coping strategies that will help them resist urges and maintain abstinence. Providing basic information about expected withdrawal symptoms and their time course will better prepare patients for success. Clinicians and counselors can provide social support during treatment by expressing concern and allowing open dialogue about the quitting process. Clinicians also can help patients identify and arrange additional social support in their environment (e.g., friends, co-workers and family members), and from trained professionals (e.g., quitline counselors).

**Pharmacotherapy—First-Line Medications**

**Bupropion Sustained Release (Bupropion SR).** Bupropion SR is available by prescription only and is the only non-nicotine medication approved by the U.S. Food and Drug Administration (FDA) for smoking-cessation treatment. It is marketed as Zyban for smoking cessation or Wellbutrin for depression. Bupropion has been shown to be effective for smoking cessation and well tolerated in a number of studies. It is contraindicated in individuals with seizure disorders, eating disorders, or who used monoamine oxidase (MAO) inhibitors within the previous two weeks. The USPHS guideline recommends it as first-line pharmacotherapy for smoking cessation, and it is the only non-nicotine medication so designated. (See Table 7.)

**Nicotine Replacement Therapies (NRTs).** NRT products are available in various forms. The active ingredient in each product is nicotine. There is no evidence of increased cardiovascular risk with NRT. The use of NRTs is contraindicated medically in cases of MI (within previous two weeks), serious arrhythmia, serious or worsening angina pectoris, and accelerated hypertension.

**Nicotine Gum.** Nicotine gum is available over the counter in 2-mg and 4-mg doses. It is absorbed best in a basic environment, and users should be advised to “park and chew” to achieve maxi-
Table 3. Assess—Determine Willingness to Make a Quit Attempt

ACTION
Ask every tobacco user if he or she is willing to make a quit attempt at this time (e.g., within the next 30 days).

STRATEGIES FOR IMPLEMENTATION
Assess patient's willingness to quit:
- If the patient is willing to make a quit attempt at this time, provide assistance (counseling and medications).
- If the patient will participate in an intensive treatment, deliver such a treatment or refer to an intensive intervention.
- If the patient clearly states he/she is unwilling to make a quit attempt at this time, provide a motivational intervention.
- If the patient is a member of a special population (e.g., adolescent, pregnant smoker, racial/ethnic minority), consider providing additional information.

maximum absorption. The dosage recommendation is to chew one piece every 1 to 2 hours for weeks 1 to 6, one piece every 2 to 4 hours for weeks 7 to 9, and one piece every 4 to 8 hours for weeks 10 to 12. The maximum dosage is 24 pieces per day. The recommended duration of treatment is 12 weeks.30

Nicotine Inhaler. Nicotine inhalers are available by prescription only. The recommended dosage of nicotine inhalers is 6-16 cartridges per day (each contains 10 mg of nicotine). The recommended duration of treatment is 12 weeks followed by a 6- to 12-week period of weaning. Therefore, six months is the maximum recommended length of therapy.30

Nicotine Lozenge. The new nicotine lozenge has been shown to have low abuse liability, not greater than the nicotine gum.31 It is available in 2-mg and 4-mg doses and should be allowed to dissolve in the mouth without chewing or swallowing. Individuals who typically smoke their first cigarette within 30 minutes of awakening should use the 4-mg dose. Because it dissolves completely, it delivers 25-27% more nicotine than the nicotine gum. In clinical trials, it increased quit rates two-fold compared with placebo, reduced cravings and withdrawal symptoms, and temporarily suppressed weight gain.32

Nicotine Nasal Spray. Nicotine nasal spray is available by prescription only. Each 10-ml spray bottle contains 100 mg of nicotine (10 mg/ml). One dose of nicotine nasal spray (two sprays, one in each nostril) contains approximately 1 mg of nicotine. The recommendation is one to two doses per hour, which may be increased to a maximum of 40 doses per day for three months, followed by tapering of the daily dose. The recommended minimum dosage is eight doses per day, and the recommended duration of treatment is up to six months.30

Nicotine Patch. Nicotine patches are available both over the counter (OTC) and by prescription. The recommended OTC and prescription nicotine patch dosage is 21 mg/day for weeks 1 to 6, tapered to 14 mg/day for weeks 7 and 8, and then tapered to 7 mg/day for weeks 9 and 10. Those smoking fewer than 10 cigarettes per day are advised to start at 14 mg/day instead of 21 mg/day. The recommended duration of treatment with nicotine patches is 8 to 10 weeks. Nicotine patches are available for 24-hour or 16-hour use.30

Pharmacotherapy—Second-line Medications
Based upon findings from the USPHS guideline panel, two medications were listed as second-line pharmacotherapies to be considered if first-line pharmacotherapies are not effective or are contraindicated.

Clonidine. Clonidine is an anti-hypertensive that has been shown in clinical trials to double quit rates compared with placebo. However, it has not been approved by the FDA for smoking cessation, nor has a specific dosing regimen been established. For these and other reasons (i.e., the side effect profile, a warning regarding abrupt discontinuation), it was recommended as a second-line agent by the guideline panel. Clinicians might consider using clonidine for patients with contraindications to using first-line medications or for patients who are unable to quit using first-line medications, but should be aware of the side effect profile and specific precautions and warnings regarding its use.

Nortriptyline. Nortriptyline is an anti-depressant that has been shown in a limited number of clinical trials to more than double quit rates compared with placebos. However, it has not been approved by the FDA for smoking cessation. The USPHS guideline panel recommended it as a second-line agent because of the limited number of studies, the lack of FDA approval for smoking cessation, and because of its side effect profile. Clinicians might consider using nortriptyline for patients who have contraindications to first-line medications or who were unable to quit smoking by using them. Clinicians should be aware of specific warnings and the side effect profile of this medication.

Multiple Therapies. Though combined NRT is not FDA approved currently, a number of studies have proven that combination therapy results in increased quit rates, and such combinations are recommended in the USPHS guideline. In addition, bupropion SR may be combined with any of the NRTs. In patients unable to quit using single therapy, combination therapy may be considered. Nicotine patch plus gum33,34 or nicotine patch plus nasal spray37 are more effective in promoting smoking cessation than a single NRT.

When to Refer to a Specialist
Despite health warnings and advice from physicians, a subgroup of smokers never quit. Difficulty quitting tobacco use has been associated with a number of characteristics, including a high level of nicotine dependence,38 comorbid psychopathology,37,38 and lower socio-economic status.39 If one of these characteristics exists, referral to smoking-cessation specialists should be considered. A high level of nicotine dependence might be predicted by one of the following conditions: smoking more than 20 cigarettes per day; smoking within 30 minutes of awakening; finding it difficult to not smoke in situations and places where smoking is prohibited; and scoring within the high range on tests of nicotine dependence, such as the Fagerstrom Tolerance Questionnaire. Comorbid psychiatric problems—especially alcohol abuse and depression—might result in poor medication compli-
Table 4. Enhancing Motivation to Quit Tobacco—
the 5 R's

**RELEVANCE**
Encourage the patient to indicate why quitting is personally relevant, being as specific as possible. Motivational information has the greatest impact if it is relevant to a patient's disease status or risk, family or social situation (e.g., having children in the home), health concerns, age, gender, and other important patient characteristics (e.g., prior quitting experience, personal barriers to cessation).

**RISKS**
The clinician should ask the patient to identify potential negative consequences of tobacco use. The clinician may suggest and highlight those that seem most relevant to the patient. The clinician should emphasize that smoking lowers low/nicotine cigarettes or use of other forms of tobacco (e.g., smokeless tobacco, cigars, and pipes) will not eliminate these risks. Examples of risks are:
- **Acute risks:** Shortness of breath, exacerbation of asthma, harm to pregnancy, impotence, infertility, increased serum carbon monoxide
- **Long-term risks:** Heart attacks and strokes, lung and other cancers (larynx, oral cavity, pharynx, esophagus, pancreas, bladder, cervix), chronic obstructive pulmonary diseases (chronic bronchitis and emphysema), long-term disability and need for extended care
- **Environmental risks:** Increased risk of lung cancer and heart disease in spouses; higher rates of smoking by children of tobacco users; increased risk for low birth weight; sudden infant death syndrome; asthma; middle ear disease; and respiratory infections in children of smokers.

**REWARDS**
The clinician should ask the patient to identify potential benefits of stopping tobacco use. The clinician may suggest and highlight those that seem most relevant to the patient. Examples of rewards are:
- Improved health
- Improved taste of food
- Improved sense of smell
- Reduced expenses
- Improved self-image
- Improved smell in home, car, clothing, and breath
- No worrying about quitting
- Positive example for kids
- Healthier babies and children
- No worrying about exposing others to smoke
- Improved physical health
- Improved performance in physical activities
- Reduced wrinkling/aging of skin

**ROADBLOCKS**
The clinician should ask the patient to identify barriers or impediments to quitting and note elements of treatment (e.g., problem-solving, pharmacotherapy) that could address barriers. Typical barriers might include:
- Withdrawal symptoms
- Fear of failure
- Weight gain
- *Lack of support
- Depression
- Enjoyment of tobacco

**REPETITION**
The motivational intervention should be repeated every time an unmotivated patient visits the clinic setting. Tobacco users who have failed in previous quit attempts should be told that most people make repeated quit attempts before they are successful.

**Ance.** Almost 20% of heavy smokers have current alcohol problems and nearly 40% of current smokers have a history of depression. Persons who live below the poverty line (lower socio-economic status) are more likely to smoke than those who live at or above the poverty line. Also, lower socio-economic status is associated with less access to cessation services, more environmental stressors, and exposure to other smokers in the social and work environment.

**Special Challenges, Controversies, Pitfalls, Areas in Need of Research**

**Symptoms and Time Course of Withdrawal as Relates to Pharmacotherapy.** While nicotine withdrawal symptoms vary from individual to individual, symptoms usually involve unpleasant effects, such as anxiety, irritability, difficulty concentrating, restlessness, impotence, hunger, tremor, racing heart, sweating, dizziness, nicotine craving, insomnia, drowsiness, headaches, digestive disturbances, and depression. Withdrawal symptoms typically increase during the first week following abstinence, then steadily improve during the next four weeks. However, smoking withdrawal is variable among individual smokers, and some individuals experience symptoms that do not improve steadily, but instead either gradually improve or show very little improvement during the typical time course. Individuals who experience withdrawal symptoms that increase or remain elevated during an extended period of time are at higher risk for relapse than those who have symptoms that steadily decline. Such individuals should be considered for prolonged therapy and allowed to use NRT beyond the recommended time period to help prevent relapse to smoking.

**Duration of Therapy.** There is no consensus among experts about the optimum duration of pharmacotherapy for treating tobacco dependence. The recommendations regarding duration of therapy with nicotine replacement medications and bupropion as outlined in the Physicians' Desk Reference (PDR) are based upon trials designed to determine effectiveness and safety of the medications, not necessarily maximum efficacy. Long-term use of pharmacotherapy (i.e., use beyond the recommended time period) might be effective for preventing relapse. For example, there is some evidence to suggest that though seven weeks of bupropion SR is effective for smoking cessation, a longer duration of treatment might prolong abstinence or time to relapse.

**Relapse Prevention (Risk Factors for Relapse).** Most relapses occur early in the quitting
Table 5. Assist—Aid the Patient in Quitting

HELP THE PATIENT WITH A QUIT PLAN.
A patient's preparations for quitting (STAR):
- Set a quit date. Ideally, the quit date should be within 2 weeks.
- Tell family, friends, and co-workers about quitting and request understanding and support.
- Anticipate challenges to planned quit attempt, particularly during the critical first few weeks. These include nicotine withdrawal symptoms.
- Remove tobacco products from your environment. Prior to quitting, avoid smoking in places where you spend a lot of time (e.g., work, home, car).

PROVIDE PRACTICAL COUNSELING [PROBLEM SOLVING/SKILLS TRAINING].
- Abstinence—Total abstinence is essential. Not even a single puff after the quit date.
- Past quit experience—Review past quit attempts including identification of what helped during the quit attempt and what factors contributed to relapse.
- Anticipate triggers or challenges in upcoming attempt—Discuss challenges/triggers and how the patient will overcome them successfully.
- Alcohol—Drinking alcohol is associated highly with relapse. The patient should consider limiting/abstaining from alcohol during the quit process.
- Other smokers in the household—The presence of other smokers in the household, particularly a spouse or partner, is associated with lower abstinence rates. Patients should encourage significant others to quit with them. If others continue to smoke, the patient should ask them to smoke outdoors and not in the quitter's presence.

PROVIDE INTRA-TREATMENT SOCIAL SUPPORT.
Provide a supportive clinical environment while encouraging the patient in his or her quit attempt. Example: "My office staff and I are available to assist you."

HELP PATIENT OBTAIN EXTRA-TREATMENT SOCIAL SUPPORT.
Help patient develop social support for his or her quit attempt in his or her environments outside of treatment. Example: "Ask your spouse/partner, friends, and co-workers to support you in your quit attempt."

RECOMMEND THE USE OF APPROVED PHARMACOTHERAPY EXCEPT IN SPECIAL CIRCUMSTANCES.
Recommend the use of pharmacotherapies found to be effective in the USPHS Guideline. (See Table 7.) Explain how these medications increase smoking cessation success and reduce withdrawal symptoms. The first-line pharmacotherapy medications include bupropion SR, nicotine gum, nicotine inhaler, nicotine nasal spray, and nicotine patch.

PROVIDE SUPPLEMENTARY MATERIALS.
- Sources—Federal agencies, nonprofit agencies, or local/state health departments.
- Type—Culturally/racially/educationally/age appropriate for the patient.
- Location—Readily available at every clinician’s workstation.

Key: Bupropion SR = bupropion sustained release

Table 6. Arrange—Schedule Follow-up Contact

 ACTION

Schedule follow-up contact, either in person or via telephone.

STRATEGIES FOR IMPLEMENTATION
Timing—Follow-up contact should occur soon after the quit date, preferably during the first week. A second follow-up contact is recommended within the first month. Schedule further follow-up contacts as indicated.

Actions during follow-up contact—Congratulate success. If tobacco use has occurred, review circumstances and elicit commitment to total abstinence. Remind patient that a lapse can be used as a learning experience. Identify problems already encountered and anticipate challenges in the immediate future. Assess pharmacotherapy use and problems. Consider use or referral to more intensive treatment.

process. Primary care physicians should engage in relapse prevention with all former smokers because patients are at risk for relapse months, and even years, after the quit date. Relapse prevention is very important soon after quitting—especially within the first three months— and can be delivered by follow-up clinical visits, follow-up telephone counseling, or using proactive tobacco quitlines. Issues that should be discussed in an effort to prevent relapse include the benefits of cessation, any successes, and any problems encountered that threaten continued abstinence. Patients should be encouraged to seek help and to report promptly any difficulties (e.g., depression, medication side effects, strong withdrawal symptoms, or lack of social support). For patients at risk for relapse, consider a prolonged course of pharmacotherapy, beyond that recommended in the PDR.

Special Populations (Gender, Adolescents, Pregnant Women, Race/Ethnic Minorities). Though research has demonstrated gender differences in smoking and cessation behavior, the USPHS guideline states that the same smoking-cessation interventions are effective for men and women and should be made available without regard to gender. Most smokers begin daily smoking as teenagers, before age 18. Many adolescent smokers report symptoms of nicotine dependence and experience withdrawal symptoms when trying to quit. Since nicotine replacement therapy is far safer than smoking, it should be considered for all smokers who need help quitting, including teens. Smoking during pregnancy is associated with serious risks to the pregnant smoker and the fetus. Although abstinence early in pregnancy will produce the greatest benefits, abstinence at any point during pregnancy is beneficial. Therefore, clinicians should offer effective smoking-cessation interventions to pregnant smokers at any and all prenatal visits. The USPHS guideline recommends that pharmacotherapy be considered when the likelihood of quitting—with its benefits for the expectant mother and fetus—outweighs the risks of the medication and continued smoking. Smoking-cessation treatments have been shown to be effective for various racial and ethnic minorities. Therefore,
Table 7. Pharmacotherapy

<table>
<thead>
<tr>
<th>MEDICATION</th>
<th>DOSAGE</th>
<th>DURATION</th>
<th>PRECAUTION</th>
<th>ADVERSE EFFECTS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bupropion SR</td>
<td>150 mg q am for 3 days; then 150 mg bid. (Begin treatment 1-2 wks pre-quit.)</td>
<td>7-12 wks Maintenance up to 6 months</td>
<td>Caution: Eating disorder</td>
<td>Insomnia, dry mouth</td>
</tr>
<tr>
<td>Nicotine gum</td>
<td>2-mg or 4-mg doses; Chew at least 1 piece q 1-2 hrs. (Acidic drinks like caffeine, juices, soda interfere with absorption.)</td>
<td>Up to 12 weeks</td>
<td>Caution: Unstable angina, 2 wks post-MI, serious arrhythmia</td>
<td>Mouth soreness, dyspepsia, hiccups (Proper technique is to “chew and park.”)</td>
</tr>
<tr>
<td>Nicotine inhaler</td>
<td>Dosage is 6-16 cartridges/day. (Acidic drinks interfere with buccal absorption.)</td>
<td>Treat up to 6 months. Begin to taper after 3 months.</td>
<td>Contraindications: None</td>
<td>Irritation in mouth and throat, cough, rhinitis</td>
</tr>
<tr>
<td>Nicotine nasal spray</td>
<td>1 spray/nostril (1 mg nicotine), 1-2 doses/hour as needed</td>
<td>Up to 8 weeks; taper during 4-6 weeks</td>
<td>Caution: Unstable angina, 2 wks post-MI, serious arrhythmia</td>
<td>Nasal irritation</td>
</tr>
<tr>
<td>Nicotine patch</td>
<td>22 mg or 21 mg/24 hrs or 15 mg/16 hrs (If sleep disturbed, wear 16-hr patch when awake.) for up to 6 weeks, then taper</td>
<td>8 to 10 weeks</td>
<td>Caution: Unstable angina, 2 wks post-MI, serious arrhythmia</td>
<td>Local skin reaction</td>
</tr>
<tr>
<td>Nicotine lozenge (was not available when guideline was published)</td>
<td>2 or 4 mg (1 lozenge every 1-2 hrs for 6 weeks; 1 lozenge every 2-4 hrs during weeks 7-9; 1 lozenge every 4-8 hrs during weeks 10-12)</td>
<td>Up to 12 weeks</td>
<td>Precautions: Uncontrolled BP, recent heart attack or irregular heartbeat, stomach ulcers or diabetes</td>
<td>Nausea, hiccups, heartburn</td>
</tr>
</tbody>
</table>

Key: SR=sustained release; bid=twice daily; MAO=monoamine oxidase; MI=myocardial infarction; BP=blood pressure.

Smokers from different racial/ethnic backgrounds should be offered effective interventions that are culturally relevant and appropriate.

**Chronic Nature of Addiction.** Tobacco dependence is a chronic disease associated with periods of abstinence and relapse that will require repeated systematic interventions. Studies have shown that it takes the average smoker four to five quit attempts before achieving smoking-cessation success. Indeed, a significant number of former smokers have difficulty maintaining abstinence and relapse back to smoking even after use of pharmacotherapy. In the first year following cessation, relapse rates of 80% have been reported. Therefore, physicians should think of tobacco dependence as a chronic disease to be managed similar to other chronic diseases—with ongoing rather than simply acute care. Factors that contribute to failed quit attempts should be addressed, and the patient should be encouraged to make another quit attempt as soon as possible. Some factors to consider are patient motivation, co-morbidities, stress, availability of social support, and use of medications.

**New Medications—Approved for Use**

**Nicotine Lozenge.** Nicotine lozenge might be a more acceptable form of oral nicotine replacement therapy than nicotine gum for patients who have difficulty chewing and parking the gum correctly. In a double-blind, placebo-controlled, randomized clinical trial, the nicotine lozenge was found to be safe and effective for
### Table 8. Clinical Guidelines for Prescribing Pharmacotherapy for Smoking Cessation

**WHO SHOULD RECEIVE PHARMACOTHERAPY FOR SMOKING CESSION?**
All smokers trying to quit except in the presence of special circumstances. Special consideration should be given before using pharmacotherapy with selected populations: those with medical contraindications, those smoking fewer than 10 cigarettes/day, those who are pregnant, and adolescent smokers.

**WHAT FIRST-LINE PHARMACOTHERAPIES ARE RECOMMENDED?**
All five of the FDA-approved pharmacotherapies for smoking cessation are recommended, including bupropion SR, nicotine gum, nicotine inhaler, nicotine nasal spray, and the nicotine patch.

**WHAT FACTORS SHOULD A CLINICIAN CONSIDER WHEN CHOOSING AMONG THE FIVE FIRST-LINE PHARMACOTHERAPIES?**
Because of the lack of sufficient data to rank-order these five medications, choice of a specific first-line pharmacotherapy must be guided by factors such as clinician familiarity with the medications, contraindications for selected patients, patient preference, previous patient experience with a specific pharmacotherapy (positive or negative), and patient characteristics (e.g., history of depression, concerns about weight gain).

**ARE PHARMACOTHERAPEUTIC TREATMENTS APPROPRIATE FOR LIGHTER SMOKERS (E.G., 10-15 CIGARETTES/DAY)?**
If pharmacotherapy is used with lighter smokers, clinicians should consider reducing the dose of first-line pharmacotherapies.

**WHAT SECOND-LINE PHARMACOTHERAPIES ARE RECOMMENDED?**
Clonidine and nortriptyline.

**WHEN SHOULD SECOND-LINE AGENTS BE USED FOR TREATING TOBACCO DEPENDENCE?**
Consider prescribing second-line agents for patients unable to use first-line medications because of contraindications or for patients for whom first-line medications are not helpful. Monitor patients for the known side effects of second-line agents.

**WHICH PHARMACOTHERAPIES SHOULD BE CONSIDERED WITH PATIENTS PARTICULARLY CONCERNED ABOUT WEIGHT GAIN?**
Bupropion SR and nicotine replacement therapies, in particular nicotine gum, have been shown to delay, but not prevent, weight gain.

**WHICH PHARMACOTHERAPIES SHOULD BE CONSIDERED WITH PATIENTS WITH A HISTORY OF DEPRESSION?**
Bupropion SR and nortriptyline appear to be effective with this population.

**SHOULD NICOTINE REPLACEMENT THERAPIES BE AVOIDED IN PATIENTS WITH A HISTORY OF CARDIOVASCULAR DISEASE?**
No. Nicotine replacement therapies are safe and have not been shown to cause adverse cardiovascular effects. However, the safety of these products has not been established for the immediate (two-week) post-MI period, with serious arrhythmias, or in patients with severe or unstable angina.

**MAY TOBACCO DEPENDENCE PHARMACOTHERAPIES BE USED LONG-TERM (E.G., 6 MONTHS OR MORE)?**
Yes. This approach may be helpful with smokers who report persistent withdrawal symptoms during the course of pharmacotherapy or who desire long-term therapy. A minority of individuals who successfully quit smoking use ad libitum NRT medications (gum, nasal spray, inhaler) long-term. The use of these medications long-term does not present a known health risk. Additionally, the FDA has approved the use of bupropion SR for a long-term maintenance indication.

**MAY PHARMACOTHERAPIES EVER BE COMBINED?**
Yes. There is evidence that combining the nicotine patch with either nicotine gum or nicotine nasal spray increases long-term abstinence rates over those produced by a single form of NRT.

---

**Key:** SR=sustained release; NRT=nicotine replacement therapy; MI=myocardial infarction.
Varenicline. Varenicline is a new kind of medication being tested by Pfizer, Inc. for smoking cessation. It has the potential to ease cravings and withdrawal symptoms without being pleasurable or addictive. It works by attaching to the nicotine receptors in the brain and letting the brain think that nicotine is attached so individuals do not experience the unpleasant symptoms of nicotine withdrawal. Also, if a former smoker lapses and smokes a cigarette, the drug has the potential to reduce the sense of satisfaction associated with smoking.51,52

Conclusions
In conclusion, tobacco use remains the leading cause of preventable morbidity and mortality in the United States. Tobacco dependence is and should be treated as a chronic disease that requires systematic, ongoing management. Effective, evidence-based strategies exist for treating this costly disease, including pharmacotherapies and behavioral therapies. Also, new and better therapies are under development.

Primary care providers are well positioned to intervene with tobacco users by implementing the strategies recommended by the USPHS guideline to provide effective clinical interventions.

References


**Physician CME Questions**

1. Which of the following medications is not one of the five FDA-approved medications recommended in the USPHS guideline as first-line pharmacotherapies for smoking cessation?
   a. Nortriptyline
   b. Nicotine patch
   c. Nicotine gum
   d. Nicotine inhaler
   e. Nicotine nasal spray

2. What are the 5 A’s for intervening with tobacco users in the primary care setting?
   a. Ask, Accept, Assist, Arrange, Advocate
   b. Ask, Advise, Assess, Assist, Arrange
   c. Approach, Advise, Assist, Administer, Arrange
   d. Ask, Advise, Assess, Assist, Accommodate
   e. Ask, Acknowledge, Advise, Assess, Admonish

3. The 5 R’s useful for motivating tobacco users to consider making a quit attempt include all of the following items except:
   a. risk
   b. relevance

---

**Primary Care Reports**

**CME Objectives**

*To help physicians:*

- summarize the most recent significant primary care medicine-related studies;
- discuss up-to-date information on all aspects of primary care, including new drugs, techniques, equipment, trials, studies, books, teaching aids, and other information pertinent to primary care;
- evaluate the credibility of published data and recommendations; and
- describe the pros and cons of new testing procedures.